-
Electronic (PDF)
-
Site License
-
Enterprisewide
Hepatitis C: Battlefield at AASLD ‘11 - Next Wave: IFN-Free Drugs with Safety and Dosing Advantage
MP Advisors, October 2011
Presentations at American Association for the Study of Liver Diseases (AASLD) 2011 (Nov. 4 - Nov. 8, San Francisco) will unveil - Data and new approaches to treat Hepatitis C Viral Infection (HCV) and offer IFN-free “All Oral options”, Combinations of New Protease Inhibitors’ (PIs), potent NS5B Polymerase inhibitors (PMIs), NS5A inhibitors and other new targets which are safer and have dosing advantage, Data from drugs for genotypes other than type1 (GT1), Drugs targeting HCV/HIV co-infected pts, difficult to treat null-responder and pts with HCV following a Liver Transplant, Opportunity in emerging markets like China - An untapped market will be the centre of attention. Roche set the trend with the acquisition of Anadys (ANDS) and amongst the small caps, we expect many names to draw attention, and stocks could rally in anticipation of partnering or acquisition news. Who will be the Future Leader in the HCV space? For more details, please read our Therapeutic Class Overview report released on 31st October, 2011 on Hepatitis C: AASLD 2011 titled “Next Wave: IFN-Free Drugs with Safety and Dosing Advantage”
- ABT-450
- ABT-072
- ABT-333
- Abbott
- BI-201335
- BI-207127
- HCV
- HCV Pipeline
- Interferon free HCV drug
- Pharmasset
- HCV/HIV Co-Infection
- HCV Pipeline
- Incivek
- Merck
- Miravirsin
- PSI-7977
- PSI-938
- Protease Inhibitors
- Presidio
- Polymerase Inhibitor
- Santaris
- Vertex
- Victrelis
- Vaniprevir
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
